FDA Updates Nivolumab Immunotherapy Dose: Every 4 Weeks at 480 mg

On 6 March 2018, FDAupdated the dose of the new-generation immunotherapy binding the cell-surface PD-1 receptor to activate immunity against cancer cells, nivolumab (brand name Opdivo) . The FDA published an update to this new-generation immunotherapy’s dose. Previously approved every 2 weeks at 240 mg, it was now approved for administration every 4 weeks at 480 mg.
-Related Topic: Immunotherapies and Cancer Vaccines
This offers oncologists and patients flexibility in personalizing treatment. Nivolumab also received approval for shorter 30-minute infusions across all approved indications.
The every-4-week (480 mg) flat-dose option was approved for:
- Metastatic melanoma (alone or in the monotherapy phase after combination with ipilimumab [Yervoy])
- Previously untreated metastatic non-small-cell lung cancer
- Advanced renal cell carcinoma following antiangiogenic treatment
- Urothelial carcinoma progressing during or after platinum chemotherapy, previously treated for locally advanced or metastatic disease
- Classical Hodgkin lymphoma relapsing or progressing after autologous stem cell transplantation (SCT) and brentuximab vedotin (Adcetris), or three or more systemic treatments including autologous SCT
- Recurrent or metastatic squamous head and neck cancer following platinum treatment
- Hepatocellular carcinoma (liver cancer) previously treated with sorafenib (Nexavar) and progressing
- Adjuvant treatment of completely resected melanoma with lymph-node involvement or metastatic disease.
-Related Topic: Common and rare cancers and oncological terms explained
Entering practice after 2012 and classified as immune checkpoint modulators, anti-CTLA-4, anti-PD-1 and anti-PD-L1 immunotherapies differ substantially in effects and side effects from conventional cytotoxic (cell-killing) drugs such as chemotherapy. Chemotherapy has shorter antitumor effects, generally a few weeks during administration, while immunotherapy may act longer and sometimes permanently. This difference raised whether longer intervals were possible, and nivolumab first gained every-4-week approval. Some patients may nevertheless need more frequent medical checks, making every-2-week administration preferable.
Related Topic:
- What are immunotherapy drug side effects, and how are they treated?
Sources
By The ASCO Post.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.